AR011285A1 - Metodo in vitro para modificar el tejido donante, el tejido donante y un tejido de injerto obtenido por dicho metodo y una composicion de material parallevar a cabo dicho metodo. - Google Patents

Metodo in vitro para modificar el tejido donante, el tejido donante y un tejido de injerto obtenido por dicho metodo y una composicion de material parallevar a cabo dicho metodo.

Info

Publication number
AR011285A1
AR011285A1 ARP970105657A ARP970105657A AR011285A1 AR 011285 A1 AR011285 A1 AR 011285A1 AR P970105657 A ARP970105657 A AR P970105657A AR P970105657 A ARP970105657 A AR P970105657A AR 011285 A1 AR011285 A1 AR 011285A1
Authority
AR
Argentina
Prior art keywords
donor tissue
photosensitizing
donor
tissue
agent
Prior art date
Application number
ARP970105657A
Other languages
English (en)
Original Assignee
Univ British Columbia
Qlt Phototherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Qlt Phototherapeutics Inc filed Critical Univ British Columbia
Publication of AR011285A1 publication Critical patent/AR011285A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Método para reducir el rechazo de aloimplantes de tejidos de donante que comprenden células con contenido de antígenos (APC) que comprende los pasos de:exponer dicho tejido del donante, modificado por tratamiento con un agente fotosensibilizador, a una luz que presenta una longitud de onda que esabsorbida por dicho agente fotosensibilizador durante un período suficiente como para disminuir la inmunogenicidad por atenuacion funcional del (APC) deltejido del donante bajo condicionesen las cuales dicha luz no es citotoxica. Al someter al tejido del donante a terapia fotodinámica se prolongo en formasignificativa la supervivencia media de los implantes, particularmente de los aloinjertos de piel. El fotosensibilizadortambién p uede ser parte de unconjugado que contiene una porcion específica del blanco de interés. Una importante clase de agentes fotosensibilizadores conocidos son los compuestosrelacionados con la porfirina; estas drogas incluyen losderivados de hematoporfirina, la fraccion de peso molecular más alto del derivado dehematoporfirina y los componentes activos de la misma, diversos derivados sintéticos de porfirinas tales como las monohidrobenzoporfirinas (DBP),porfirinasverdes; y otros varios compuestos policíclicos que se cree que generan singulete de oxígeno cuando se los irradia. El uso de estos agentesfotosensiblizadores para destruir la capacidad del tejido de donante de iniciar unareaccion inje rto contra huésped se intensifica mediantela conjungacion del fotosensiblizante con un agente buscador del blanco específico. En especial, el material fotosensibilizante se puede conjugar con(1) una porcion que tengaespecíficamente como blan co las células que presentan antígenos (APC) directamente en el tejido de donante; (2) una porcion
ARP970105657A 1996-12-02 1997-12-02 Metodo in vitro para modificar el tejido donante, el tejido donante y un tejido de injerto obtenido por dicho metodo y una composicion de material parallevar a cabo dicho metodo. AR011285A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/759,318 US5882328A (en) 1995-01-13 1996-12-02 Method to prevent transplant rejection

Publications (1)

Publication Number Publication Date
AR011285A1 true AR011285A1 (es) 2000-08-16

Family

ID=25055212

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105657A AR011285A1 (es) 1996-12-02 1997-12-02 Metodo in vitro para modificar el tejido donante, el tejido donante y un tejido de injerto obtenido por dicho metodo y una composicion de material parallevar a cabo dicho metodo.

Country Status (4)

Country Link
US (1) US5882328A (es)
AR (1) AR011285A1 (es)
AU (1) AU5219198A (es)
WO (1) WO1998024476A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8409846B2 (en) 1997-09-23 2013-04-02 The United States Of America As Represented By The Department Of Veteran Affairs Compositions, methods and devices for maintaining an organ
US7229447B1 (en) 1998-08-25 2007-06-12 Advanced Photodynamics Technologies, Inc. Photodynamic therapy utilizing a solution of photosensitizing compound and surfactant
US6364907B1 (en) 1998-10-09 2002-04-02 Qlt Inc. Method to prevent xenograft transplant rejection
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US6454789B1 (en) 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
CA2356532A1 (en) 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US6793677B2 (en) * 1999-08-13 2004-09-21 Bret A. Ferree Method of providing cells and other biologic materials for transplantation
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
WO2001051087A2 (en) * 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
JP2003531828A (ja) 2000-02-26 2003-10-28 アドバンスト フォトダイナミック テクノロジーズ， インコーポレイテッド 光感光性物質および界面活性剤を使用する、光力学的な細胞および無細胞生物の根絶
US6592618B2 (en) * 2000-02-29 2003-07-15 The Brigham And Women's Hospital, Inc. In vitro modification of cardiac valvular xenografts
US6235796B1 (en) 2000-06-26 2001-05-22 Sarfaraz K. Niazi Use of fluorocarbons for the prevention of surgical adhesions
WO2002064163A2 (en) 2001-02-15 2002-08-22 Qlt Inc. Reduction or prevention of pdt related inflammation
AU2002332697A1 (en) * 2001-12-12 2003-06-23 Leon J. Lewandowski Photophoretic auto immune stimulation
JP2005527493A (ja) * 2002-01-23 2005-09-15 ライト サイエンシーズ コーポレイション 光線力学療法のためのシステムおよび方法
US8304181B2 (en) 2004-10-07 2012-11-06 Transmedics, Inc. Method for ex-vivo organ care and for using lactate as an indication of donor organ status
US12010987B2 (en) 2004-10-07 2024-06-18 Transmedics, Inc. Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status
IL273422B (en) 2004-10-07 2022-07-01 Transmedics Inc Methods and systems for extracorporeal organ treatment
US9301519B2 (en) * 2004-10-07 2016-04-05 Transmedics, Inc. Systems and methods for ex-vivo organ care
US20070010897A1 (en) * 2005-01-06 2007-01-11 Stone Kevin R Immunochemically modified and sterilized xenografts and allografts
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
US9078428B2 (en) 2005-06-28 2015-07-14 Transmedics, Inc. Systems, methods, compositions and solutions for perfusing an organ
ES2772676T3 (es) * 2006-04-19 2020-07-08 Transmedics Inc Sistema de cuidado de órganos ex vivo
US9457179B2 (en) * 2007-03-20 2016-10-04 Transmedics, Inc. Systems for monitoring and applying electrical currents in an organ perfusion system
US9247728B2 (en) * 2008-01-31 2016-02-02 Transmedics, Inc. Systems and methods for ex vivo lung care
US9174065B2 (en) * 2009-10-12 2015-11-03 Kona Medical, Inc. Energetic modulation of nerves
US9119951B2 (en) 2009-10-12 2015-09-01 Kona Medical, Inc. Energetic modulation of nerves
US8986211B2 (en) 2009-10-12 2015-03-24 Kona Medical, Inc. Energetic modulation of nerves
US20160059044A1 (en) 2009-10-12 2016-03-03 Kona Medical, Inc. Energy delivery to intraparenchymal regions of the kidney to treat hypertension
US20110118600A1 (en) 2009-11-16 2011-05-19 Michael Gertner External Autonomic Modulation
US8295912B2 (en) 2009-10-12 2012-10-23 Kona Medical, Inc. Method and system to inhibit a function of a nerve traveling with an artery
US20110092880A1 (en) * 2009-10-12 2011-04-21 Michael Gertner Energetic modulation of nerves
US8469904B2 (en) 2009-10-12 2013-06-25 Kona Medical, Inc. Energetic modulation of nerves
US11998266B2 (en) 2009-10-12 2024-06-04 Otsuka Medical Devices Co., Ltd Intravascular energy delivery
US8986231B2 (en) 2009-10-12 2015-03-24 Kona Medical, Inc. Energetic modulation of nerves
DK2704560T3 (da) 2011-04-14 2022-05-23 Transmedics Inc Organbehandlingsopløsning til maskinperfusion ex-vivo af donorlunger
DK3151663T3 (da) 2014-06-02 2020-11-30 Transmedics Inc Ex vivo-organplejesystem
US10925579B2 (en) 2014-11-05 2021-02-23 Otsuka Medical Devices Co., Ltd. Systems and methods for real-time tracking of a target tissue using imaging before and during therapy delivery
CA2970117A1 (en) 2014-12-12 2016-06-16 Darren FREED Apparatus and method for organ perfusion
CN107949419B (zh) 2015-09-09 2021-03-05 特兰斯迈迪茨公司 离体器官护理系统用的主动脉插管

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579120A (en) * 1975-08-05 1980-11-12 Union International Co Ltd Extracts of the haemopoietic system
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4946438A (en) * 1983-09-01 1990-08-07 The Trustees Of Columbia University In The City Of New York Process for development of acceptance of transplanted organs and tissues
US4683295A (en) * 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies
NO166836C (no) * 1985-03-14 1991-09-11 Univ California Fremgangsmaate for behandling av et organtransplantat.
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4838852A (en) * 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US4961920A (en) * 1988-12-08 1990-10-09 Luminis Pty, Ltd. Phototherapeutic monovinyl and divinyl ether-linked dimers
US5028594A (en) * 1988-12-27 1991-07-02 Naxcor Use of photodynamic compositions for cytotoxic effects
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5173504A (en) * 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5171741A (en) * 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5308608A (en) * 1989-06-07 1994-05-03 University Of British Columbia Photosensitizing Diels-Alder porphyrin derivatives
US5149708A (en) * 1989-06-07 1992-09-22 University Of British Columbia Photosensitizing Diels-Alder porphyrin derivatives
US5064952A (en) * 1990-01-16 1991-11-12 Board Of Trustees, A Constitutional Corporation Operating Michigan State University Derivatives of porphyrin useful in photodynamic therapy
US5087636A (en) * 1990-02-20 1992-02-11 University Of British Columbia Method to destroy malignant cells in mononuclear cell populations
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5238940A (en) * 1990-03-22 1993-08-24 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5147289A (en) * 1990-03-29 1992-09-15 Therakos, Inc Non-specific immune system enhancement
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5192312A (en) * 1991-03-05 1993-03-09 Colorado State University Research Foundation Treated tissue for implantation and methods of treatment and use
US5545423A (en) * 1991-11-25 1996-08-13 Vivorx, Inc. Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
US5244914A (en) * 1992-04-27 1993-09-14 American Cyanamid Company Stable porfimer sodium compositions and methods for their manufacture
US5820872A (en) * 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
US5368841A (en) * 1993-02-11 1994-11-29 The General Hospital Corporation Photodynamic therapy for the destruction of the synovium in the treatment of rheumatoid arthritis and the inflammatory arthritides
US5563132A (en) * 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
NZ298355A (en) * 1995-01-13 2000-02-28 Univ British Columbia Method of reducing allograft transplant rejection by contacting donor tissue with photosensitizing agent followed by light
US5824080A (en) * 1995-09-28 1998-10-20 The General Hospital Corporation Photochemistry for the preparation of biologic grafts--allografts and xenografts

Also Published As

Publication number Publication date
US5882328A (en) 1999-03-16
AU5219198A (en) 1998-06-29
WO1998024476A1 (en) 1998-06-11

Similar Documents

Publication Publication Date Title
AR011285A1 (es) Metodo in vitro para modificar el tejido donante, el tejido donante y un tejido de injerto obtenido por dicho metodo y una composicion de material parallevar a cabo dicho metodo.
Peplow et al. Photodynamic modulation of wound healing: a review of human and animal studies
US5913884A (en) Inhibition of fibrosis by photodynamic therapy
KR970705413A (ko) 암의 광역학요법용 새로운 로다민 유도체 및 백혈병의 시험관내 정화(novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias)
Müller et al. Enhanced photodynamic effects using fractionated laser light
Fingar et al. Drug and light dose dependence of photodynamic therapy: a study of tumor and normal tissue response
ES2244995T3 (es) Dispositivo para la irradiacion de luz sobre tejido.
Gomer et al. Molecular, cellular, and tissue responses following photodynamic therapy
Henderson et al. Bacteriochlorophyll-a as photosensitizer for photodynamic treatment of transplantable murine tumors
US6008241A (en) Green porphyrins as immunomodulators
US6107325A (en) Green porphyrins as immunomodulators
Fingar et al. The effects of photodynamic therapy using differently substituted zinc phthalocyanines on vessel constriction, vessel leakage and tumor response
Cowled et al. Comparison of the efficacy of pulsed and continuous‐wave red laser light in induction of photocytotoxicity by haematoporphyrin derivative
Powers et al. Laser photochemotherapy of rhodamine-123 sensitized human glioma cells in vitro
Brasseur et al. Eradication of Multiple Myeloma and Breast Cancer Cells by TH9402‐mediated Photodynamic Therapy: Implication for Clinical Ex Vivo Purging of Autologous Stem Cell Transplants¶
Aires-Fernandes et al. Tissue engineering and photodynamic therapy: A new frontier of science for clinical application-an up-to-date review
US20060234959A1 (en) Photodynamic therapy utilizing multiple duty cycle light modulation
ES2291035T3 (es) Sinergismo de efectos dinamicos y de electropermeabilizacion sobre la vitalidad celular como nuevo agente citotoxico.
Waterfield et al. Wavelength‐dependent effects of benzoporphyrin derivative monoacid ring A in vivo and in vitro
Camps Jr et al. Photodynamic therapy of prostate cancer: an in vitro study
Hendrich et al. Photodynamic therapy for rheumatoid arthritis?
ES2227578T3 (es) Procedimiento para prevenir el rechazo de transplantes.
Tomio et al. Effect of hematoporphyrin and red light on AH-130 solid tumors in rats
Stuart Nelson et al. Study of the in vivo and in vitro photosensitizing capabilities of uroporphyrin I compared to photofrin II
JPH01221327A (ja) 形質転換又は腫瘍細胞を選択的に死滅させるための剤として使用されるセット又はキット

Legal Events

Date Code Title Description
FA Abandonment or withdrawal